ORM2

Summary

ORM2 (orosomucoid 2, HGNC:8499) is a protein-coding gene on chromosome 9q32, encoding Alpha-1-acid glycoprotein 2 (P19652). Functions as a transport protein in the blood stream.

This gene encodes a key acute phase plasma protein. Because of its increase due to acute inflammation, this protein is classified as an acute-phase reactant. The specific function of this protein has not yet been determined; however, it may be involved in aspects of immunosuppression.

Source: NCBI Gene 5005 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 21 total
• Druggable target: yes
• MANE Select transcript: NM_000608

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8499
Approved symbol	ORM2
Name	orosomucoid 2
Location	9q32
Locus type	gene with protein product
Status	Approved
Aliases	AGP-B, AGP-B’, AGP2
Ensembl gene	ENSG00000228278
Ensembl biotype	protein_coding
OMIM	138610
Entrez	5005

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 protein_coding

ENST00000431067, ENST00000893195, ENST00000893196, ENST00000893197, ENST00000893198, ENST00000893199, ENST00000893200, ENST00000893201, ENST00000893202, ENST00000893203

RefSeq mRNA: 1 — MANE Select: NM_000608 NM_000608

CCDS: CCDS6804

Canonical transcript exons

ENST00000431067 — 6 exons

Exon	Start	End
ENSE00001652131	114331826	114331929
ENSE00001661610	114330434	114330576
ENSE00001828785	114333069	114333251
ENSE00001882975	114329869	114330018
ENSE00003564083	114331567	114331674
ENSE00003647498	114330792	114330862

Expression profiles

Bgee: expression breadth ubiquitous, 158 present calls, max score 99.92.

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	99.92	gold quality
liver	UBERON:0002107	99.52	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.27	silver quality
bone marrow	UBERON:0002371	78.93	gold quality
body of stomach	UBERON:0001161	78.27	gold quality
granulocyte	CL:0000094	76.22	gold quality
stomach	UBERON:0000945	74.05	gold quality
right lung	UBERON:0002167	73.10	gold quality
blood	UBERON:0000178	72.44	gold quality
bone marrow cell	CL:0002092	71.73	gold quality
upper lobe of left lung	UBERON:0008952	70.97	gold quality
right adrenal gland	UBERON:0001233	70.92	gold quality
spleen	UBERON:0002106	69.86	gold quality
upper lobe of lung	UBERON:0008948	69.86	gold quality
fundus of stomach	UBERON:0001160	69.34	gold quality
leukocyte	CL:0000738	68.80	gold quality
prostate gland	UBERON:0002367	68.67	gold quality
monocyte	CL:0000576	68.54	gold quality
mononuclear cell	CL:0000842	68.37	gold quality
right uterine tube	UBERON:0001302	67.08	gold quality
left adrenal gland	UBERON:0001234	66.77	gold quality
vermiform appendix	UBERON:0001154	65.40	gold quality
right adrenal gland cortex	UBERON:0035827	64.59	gold quality
left adrenal gland cortex	UBERON:0035825	64.50	gold quality
lower esophagus mucosa	UBERON:0035834	63.96	gold quality
adrenal gland	UBERON:0002369	63.71	gold quality
adrenal cortex	UBERON:0001235	62.82	gold quality
small intestine Peyer’s patch	UBERON:0003454	61.48	gold quality
caecum	UBERON:0001153	61.47	gold quality
endocervix	UBERON:0000458	61.45	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-9	yes	8312.28
E-MTAB-10553	yes	3753.24
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR

miRNA regulators (miRDB)

16 targeting ORM2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-4643	99.49	67.63	1791
HSA-MIR-6515-5P	97.08	65.48	1219
HSA-MIR-3126-5P	96.87	65.83	912
HSA-MIR-6875-5P	96.87	65.49	958

Literature-anchored findings (GeneRIF, showing 21)

• structure of the alpha1-acid glycoprotein (AGP), or orosomucoid (ORM), gene was investigated in a Ghanaian mother and her child, who shared an unusual variant, ORM1 S2(C), found by isoelectric focusing (PMID:11587070)
• folds as a highly symmetrical all-beta protein dominated by a single eight-stranded antiparallel beta-sheet (PMID:12480518)
• the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site (PMID:15863355)
• The binding of coumarin enantiomers to ORM2 is studied. (PMID:16290938)
• Results describe the thermal unfolding and reversibility of temperature-induced changes in alpha(1)-acid glycoprotein. (PMID:16331959)
• A different distribution of the area percentage of AGP forms is observed when comparing samples from diseased and healthy individuals, the most acidic AGP forms being present in a higher proportion in the samples from cancer patients. (PMID:17987628)
• The results indicate that, in accordance with prior expectations, the ORM2 variant is responsible for the acute-phase property of alpha-1 acid glycoprotein. (PMID:19018521)
• Characterized are more than 150 human Alpha-1-acid glycoprotein isoforms, differing both in the amino acid sequence and in the glycosylation. (PMID:20617306)
• Identify ORM genetic variations/haplotype structure associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients. (PMID:21638284)
• Alteration in expression of ORM2 suggests that ORM2 could be used as a potential biomarker in the diagnosis of colorectal cancer. (PMID:22363757)
• Data suggest that human serum albumin (HSA) might serve as a carrier in delivering chitooligomers to target tissues than alpha-1-glycoprotein (AGP) which has pharmacological importance. (PMID:24359035)
• These findings suggest that the ORM distal promoter region differentially regulates expression of ORM genes at basal level and in acute phase responses. (PMID:24389491)
• Data indicate that the band intensity of sialic acid content in alpha-1 Acid glycoprotein (AGP) of alcoholic liver cirrhosis was found to be lower than that in pooled control group. (PMID:25408356)
• Low ORM2 expression is associated with metastasis in hepatocellular carcinoma. (PMID:25965830)
• Neural cell interactions are important for brain physiology and pathology. Particularly, the interaction between non-neuronal cells plays a central role in regulating brain inflammation, which is closely linked to many brain disorders. Here, we newly identified orosomucoid-2 (ORM2) as an endogenous protein that mediates such non-neuronal glial cell interactions (PMID:28193696)
• Studies suggest plasma alpha-1-acid glycoprotein (AAG) as a potential predictive biomarker of docetaxel non-haematological AEs namely oral mucositis and rash. (PMID:28554261)
• the glycosylation change of alpha-1-acid glycoprotein (AGP) in hepatocellular carcinoma (HCC), cirrhosis and controls (PMID:28621608)
• Urinary ORM-2 and sCD14 levels were increased in patients with Rheumatoid Arthritis and were correlated with the disease activity. (PMID:30600953)
• Orosomucoid in liver diseases. (PMID:34963738)
• Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia. (PMID:36198834)
• Influence of Intrauterine Inflammation, Delivery, and Postnatal Feeding on the Temporal Changes of Serum Alpha 1 Acid Glycoprotein Levels in Extremely-Low-Birth-Weight Infants. (PMID:36501194)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	apom	ENSDARG00000076838
mus_musculus	Orm3	ENSMUSG00000028359
mus_musculus	Orm1	ENSMUSG00000039196
mus_musculus	Orm2	ENSMUSG00000061540
rattus_norvegicus	Orm1	ENSRNOG00000007886

Paralogs (1): ORM1 (ENSG00000229314)

Protein

Protein identifiers

Alpha-1-acid glycoprotein 2 — P19652 (reviewed: P19652)

Alternative names: Orosomucoid-2

All UniProt accessions (1): P19652

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability. Appears to function in modulating the activity of the immune system during the acute-phase reaction.

Subcellular location. Secreted.

Tissue specificity. Expressed by the liver and secreted in plasma.

Post-translational modifications. N-glycosylated. N-glycan heterogeneity at Asn-33: Hex5HexNAc4 (minor), Hex6HexNAc5 (major) and dHex1Hex6HexNAc5 (minor).

Domain organisation. Contains a beta-barrel that binds various ligands in its interior.

Induction. Synthesis is controlled by glucocorticoids, interleukin-1 and interleukin-6, It increases 5- to 50-fold upon inflammation.

Polymorphism. Many different variants of ORM2 are known.

Similarity. Belongs to the calycin superfamily. Lipocalin family.

RefSeq proteins (1): NP_000599* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000566	Lipocln_cytosolic_FA-bd_dom	Domain
IPR001500	A1A_glycop	Family
IPR012674	Calycin	Homologous_superfamily

Pfam: PF00061

UniProt features (39 total): strand 8, helix 6, sequence variant 5, sequence conflict 5, turn 5, glycosylation site 5, disulfide bond 2, signal peptide 1, chain 1, modified residue 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
7OUB	X-RAY DIFFRACTION	1.82
3APU	X-RAY DIFFRACTION	2.1
3APV	X-RAY DIFFRACTION	2.15
3APW	X-RAY DIFFRACTION	2.2
3APX	X-RAY DIFFRACTION	2.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P19652-F1	91.68	0.84

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 19

Disulfide bonds (2): 23–165, 90–183

Glycosylation sites (5): 33, 56, 72, 93, 103

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-114608	Platelet degranulation
R-HSA-6798695	Neutrophil degranulation
R-HSA-109582	Hemostasis
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-76002	Platelet activation, signaling and aggregation
R-HSA-76005	Response to elevated platelet cytosolic Ca2+

MSigDB gene sets: 93 (showing top): MODULE_52, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GNF2_GSTM1, GOCC_SECRETORY_GRANULE, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, MODULE_45, GNF2_HPN, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, MODULE_16, GOBP_INTERLEUKIN_1_PRODUCTION, GOBP_POSITIVE_REGULATION_OF_TUMOR_NECROSIS_FACTOR_SUPERFAMILY_CYTOKINE_PRODUCTION, MODULE_66, MODULE_118, MODULE_75

GO Biological Process (5): regulation of immune system process (GO:0002682), acute-phase response (GO:0006953), positive regulation of interleukin-1 beta production (GO:0032731), positive regulation of interleukin-1 production (GO:0032732), positive regulation of tumor necrosis factor production (GO:0032760)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), platelet alpha granule lumen (GO:0031093), azurophil granule lumen (GO:0035578), specific granule lumen (GO:0035580), extracellular exosome (GO:0070062), blood microparticle (GO:0072562)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Response to elevated platelet cytosolic Ca2+	1
Innate Immune System	1
Immune System	1
Hemostasis	1
Platelet activation, signaling and aggregation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
secretory granule lumen	3
cellular anatomical structure	2
immune system process	1
regulation of biological process	1
acute inflammatory response	1
interleukin-1 beta production	1
regulation of interleukin-1 beta production	1
positive regulation of interleukin-1 production	1
positive regulation of cytokine production	1
interleukin-1 production	1
regulation of interleukin-1 production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
positive regulation of tumor necrosis factor superfamily cytokine production	1
binding	1
platelet alpha granule	1
vacuolar lumen	1
azurophil granule	1
specific granule	1
extracellular vesicle	1
extracellular region	1

Protein interactions and networks

STRING

1136 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ORM2	ALB	P02768	998
ORM2	SERPINA1	P01009	949
ORM2	HP	P00737	929
ORM2	CP	P00450	898
ORM2	CRP	P02741	869
ORM2	ORMDL1	Q9P0S3	851
ORM2	AHSG	P02765	849
ORM2	AMBP	P00977	840
ORM2	SERPINA3	P01011	830
ORM2	ORMDL2	Q53FV1	820
ORM2	A2M	P01023	798
ORM2	TTR	P02766	797
ORM2	APOA1	P02647	778
ORM2	ORMDL3	Q8N138	774
ORM2	HPX	P02790	770

IntAct

22 interactions, top by confidence:

A	B	Type	Score
ORM1	ORM2	psi-mi:“MI:0914”(association)	0.620
ORM2	ORM1	psi-mi:“MI:0915”(physical association)	0.620
ORM1	ORM2	psi-mi:“MI:0915”(physical association)	0.620
	LECT2	psi-mi:“MI:0915”(physical association)	0.400
STK3	ORM2	psi-mi:“MI:0915”(physical association)	0.370
CYP39A1	ORM2	psi-mi:“MI:0915”(physical association)	0.370
PRDX6	ORM2	psi-mi:“MI:0915”(physical association)	0.370
GDPD1	CP	psi-mi:“MI:0914”(association)	0.350
GNG8	POTEF	psi-mi:“MI:0914”(association)	0.350
PPP2R2B	A2ML1	psi-mi:“MI:0914”(association)	0.350
CDKN1B	YKT6	psi-mi:“MI:0914”(association)	0.350
PHF11	A2ML1	psi-mi:“MI:0914”(association)	0.350
RHBDD1	A2ML1	psi-mi:“MI:0914”(association)	0.350
P2RX6	A2ML1	psi-mi:“MI:0914”(association)	0.350
MATN2	IGLL5	psi-mi:“MI:0914”(association)	0.350
UBE2U	IGLL5	psi-mi:“MI:0914”(association)	0.350
KLK10	IGLL5	psi-mi:“MI:0914”(association)	0.350
SCGB1D1	IGLL5	psi-mi:“MI:0914”(association)	0.350
		psi-mi:“MI:0914”(association)	0.350

BioGRID (21): ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM2 (Affinity Capture-MS), ORM1 (Affinity Capture-MS)

ESM2 similar proteins: A2AEP0, A2AJB7, A2BIM8, B5X0G2, F0UZ12, H2B3G5, O08976, O18874, P02762, P02763, P02764, P04938, P06910, P06911, P07361, P07435, P08937, P09465, P11588, P11589, P11591, P14630, P15399, P19652, P20462, P21350, P21352, P21760, P35578, P81245, P81608, P83508, Q28133, Q29144, Q29147, Q29614, Q2LE37, Q3SZR3, Q5R894, Q5VFH6

Diamond homologs: P02763, P02764, P07361, P19652, P21350, P21352, P25227, Q3SZR3, Q60590, Q63805

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
NPR1	“up-regulates activity”	ORM2	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

21 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	14
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

641 predictions. Top by Δscore:

Variant	Effect	Δscore
9:114330017:GG:G	donor_gain	1.0000
9:114330018:GG:G	donor_gain	1.0000
9:114330772:C:CA	acceptor_gain	1.0000
9:114330779:T:TA	acceptor_gain	1.0000
9:114330780:G:A	acceptor_gain	1.0000
9:114330790:A:AG	acceptor_gain	1.0000
9:114330791:G:GG	acceptor_gain	1.0000
9:114330858:A:G	donor_gain	1.0000
9:114331563:CCA:C	acceptor_loss	1.0000
9:114331565:A:AG	acceptor_gain	1.0000
9:114331565:AGAG:A	acceptor_gain	1.0000
9:114331565:AGAGG:A	acceptor_gain	1.0000
9:114331566:G:GG	acceptor_gain	1.0000
9:114331566:GA:G	acceptor_gain	1.0000
9:114331566:GAGG:G	acceptor_gain	1.0000
9:114331566:GAGGG:G	acceptor_gain	1.0000
9:114331821:T:TA	acceptor_gain	1.0000
9:114331821:TGCA:T	acceptor_loss	1.0000
9:114331822:GCAG:G	acceptor_loss	1.0000
9:114331823:CAGCT:C	acceptor_loss	1.0000
9:114331824:A:AG	acceptor_gain	1.0000
9:114331824:AGCT:A	acceptor_gain	1.0000
9:114331825:G:GT	acceptor_gain	1.0000
9:114331825:GC:G	acceptor_gain	1.0000
9:114331825:GCT:G	acceptor_gain	1.0000
9:114331825:GCTG:G	acceptor_gain	1.0000
9:114331825:GCTGA:G	acceptor_gain	1.0000
9:114331928:AG:A	donor_loss	1.0000
9:114331929:GGTAA:G	donor_loss	1.0000
9:114331930:GT:G	donor_loss	1.0000

AlphaMissense

1315 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:114330449:T:C	F44L	0.980
9:114330451:T:A	F44L	0.980
9:114330451:T:G	F44L	0.980
9:114330802:T:A	C90S	0.978
9:114330803:G:C	C90S	0.978
9:114330446:T:A	W43R	0.975
9:114330446:T:C	W43R	0.975
9:114330448:G:C	W43C	0.973
9:114330448:G:T	W43C	0.973
9:114330802:T:C	C90R	0.973
9:114333075:T:A	C183S	0.973
9:114333076:G:C	C183S	0.973
9:114331864:T:C	F159L	0.969
9:114331866:C:A	F159L	0.969
9:114331866:C:G	F159L	0.969
9:114331865:T:C	F159S	0.966
9:114330804:C:G	C90W	0.962
9:114330515:T:C	F66L	0.961
9:114330517:C:A	F66L	0.961
9:114330517:C:G	F66L	0.961
9:114330459:C:A	A47E	0.958
9:114333075:T:C	C183R	0.957
9:114330461:T:C	S48P	0.952
9:114330803:G:A	C90Y	0.951
9:114329935:A:C	S11R	0.948
9:114329937:C:A	S11R	0.948
9:114329937:C:G	S11R	0.948
9:114331865:T:G	F159C	0.947
9:114333076:G:A	C183Y	0.946
9:114330803:G:T	C90F	0.944

dbSNP variants (sampled 300 via entrez): RS1001633471 (9:114333351 GC>G,GCC), RS1002905971 (9:114332357 A>C,G), RS1004687526 (9:114333312 G>A,C), RS1005038826 (9:114333003 G>A,C), RS1006408131 (9:114332319 T>C,G), RS1006767272 (9:114332003 G>A), RS1006857116 (9:114332835 G>A), RS1007600038 (9:114331711 T>C,G), RS1007805037 (9:114331560 C>T), RS1008860480 (9:114330775 C>G,T), RS1010213017 (9:114332615 T>C), RS1010495778 (9:114331321 C>A,G), RS1010546722 (9:114331499 C>A,T), RS1012509877 (9:114331269 A>C), RS1014134401 (9:114329636 C>T)

Disease associations

OMIM: gene MIM:138610 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5958 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2250242	Metabolism/PK	3	docetaxel	Prostatic Neoplasms

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1687390	ORM1, ORM2		0.00	0
rs2250242	AKNA, ORM2	3	1.00	1	docetaxel

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Folic Acid	decreases expression, affects cotreatment, increases expression	2
Valproic Acid	decreases expression, decreases methylation, increases expression	2
Cyclosporine	increases expression, decreases expression	2
methylmercuric chloride	increases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
sodium arsenite	decreases expression	1
benazol P	affects expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
acyline	decreases expression	1
entinostat	decreases expression	1
K 7174	decreases expression	1
belinostat	decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Panobinostat	decreases expression	1
Ethanol	affects cotreatment, increases expression	1
Benzo(a)pyrene	decreases expression	1
Cadmium	affects binding	1
Calcitriol	increases expression, affects cotreatment	1
Chlorpromazine	affects binding, decreases reaction	1
Dipyridamole	affects binding, decreases reaction	1
Disopyramide	affects binding, decreases reaction	1
Imipramine	decreases reaction, affects binding	1
Lead	affects binding	1
Lidocaine	affects binding, decreases reaction	1
Methadone	decreases reaction, affects binding	1
Nickel	affects binding	1
Phenylmercuric Acetate	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL936357	Binding	Binding affinity to human ORM2 at 37 degC by induced circular dichroism method	Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.